Data from A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

MLA

Carlos L. Arteaga, et al. Data from A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.c.6527076.v1.

APA

Carlos L. Arteaga, Dalila Sellami, Florian D. Vogl, Ivan Diaz-Padilla, Laure Charbonnier, Naveen Babbar, Frankie Holmes, Christoph Mundhenke, Sherko Kümmel, Peter A. van Dam, Laura García Estévez, Sara Hurvitz, Christian F. Singer, Eric P. Winer, Antonio C. Wolff, Marco Colleoni, Peter A. Fasching, Michael Gnant, J. Alejandro Pérez Fidalgo, … Ingrid A. Mayer. (2023). Data from A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). https://doi.org/10.1158/1078-0432.c.6527076.v1

Chicago

Carlos L. Arteaga, Dalila Sellami, Florian D. Vogl, Ivan Diaz-Padilla, Laure Charbonnier, Naveen Babbar, Frankie Holmes, et al. 2023. “Data from A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB),” March. doi:10.1158/1078-0432.c.6527076.v1.